Puma Biotech Beats Q4 Estimates: EPS 20.8% Above, Revenues +11%
Q4 adjusted earnings rose to $0.29 per share, beating estimates by 20.8%, while revenues climbed 27.7% year-over-year to $75.5 million, topping consensus by 11.3%. Puma Biotech has surpassed EPS and revenue forecasts in each of the last four quarters, and its shares have gained 29.1% year-to-date.
1. Q4 Financial Results
Puma Biotech reported adjusted EPS of $0.29 for Q4, surpassing the $0.24 consensus by 20.8%, while revenue advanced 27.7% year-over-year to $75.5 million, an 11.3% beat versus analyst forecasts.
2. Consistent Beat History
The company has exceeded consensus EPS and revenue estimates in each of the last four quarters, including a 133.3% earnings surprise in the prior period, reflecting sustained operational momentum.
3. Share Performance and Outlook
Shares have climbed 29.1% year-to-date versus a 1.5% gain for the S&P 500, and investors will focus on management’s commentary and updated consensus for next quarter’s $0.11 EPS on $48.0 million revenue estimate.